Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in multiple investor conferences during September 2025.
The company's leadership team, including CEO Arthur T. Sands, CFO Hans van Houte, CCO John Northcott, and CBO Jason Kantor, will attend five major healthcare conferences: Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley, and Stifel Virtual Immunology Forum. All presentations will be webcast live and available for 30 days through Nurix's website.
Nurix Therapeutics (Nasdaq: NRIX), societ脿 biofarmaceutica in fase clinica specializzata in terapie basate sulla degradazione mirata delle proteine, ha comunicato la sua partecipazione a diversi incontri con investitori previsti per settembre 2025.
Il team dirigenziale, composto dal CEO Arthur T. Sands, dal CFO Hans van Houte, dal CCO John Northcott e dal CBO Jason Kantor, prender脿 parte a cinque importanti conferenze nel settore sanitario: Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley e allo Stifel Virtual Immunology Forum. Tutte le presentazioni saranno trasmesse in diretta via webcast e resteranno disponibili per 30 giorni sul sito web di Nurix.
Nurix Therapeutics (Nasdaq: NRIX), una compa帽铆a biofarmac茅utica en fase cl铆nica especializada en medicamentos basados en la degradaci贸n selectiva de prote铆nas, ha anunciado su participaci贸n en varias conferencias para inversores en septiembre de 2025.
El equipo directivo, que incluye al CEO Arthur T. Sands, el CFO Hans van Houte, el CCO John Northcott y el CBO Jason Kantor, asistir谩 a cinco destacadas conferencias de salud: Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley y el Stifel Virtual Immunology Forum. Todas las presentaciones se transmitir谩n en vivo por webcast y estar谩n disponibles durante 30 d铆as en la p谩gina web de Nurix.
Nurix Therapeutics (Nasdaq: NRIX)電� 響滌爜 雼氨歆� 攵勴暣 旮半皹 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎届偓搿�, 2025雲� 9鞗旍棎 鞓堨爼霅� 鞐煬 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
CEO Arthur T. Sands毳� 牍勲’頃� 瓴届榿歆勳澑 CFO Hans van Houte, CCO John Northcott, CBO Jason Kantor臧� Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley 氚� Stifel Virtual Immunology Forum 霌� 雼れ劘 臧� 欤检殧 項姢旒�鞏� 旖橅嵓霟办姢鞐� 彀胳劃頃╇媹雼�. 氇摖 氚滍憸電� 鞗轨簮鞀ろ姼搿� 靸濎瓿�霅橂┌ Nurix 鞗轨偓鞚错姼鞐愳劀 30鞚缄皠 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Nurix Therapeutics (Nasdaq: NRIX), soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans des m茅dicaments fond茅s sur la d茅gradation cibl茅e des prot茅ines, a annonc茅 sa participation 脿 plusieurs conf茅rences pour investisseurs en septembre 2025.
L'茅quipe dirigeante, comprenant le CEO Arthur T. Sands, le CFO Hans van Houte, le CCO John Northcott et le CBO Jason Kantor, assistera 脿 cinq grandes conf茅rences du secteur de la sant茅 : Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley et le Stifel Virtual Immunology Forum. Toutes les pr茅sentations seront diffus茅es en direct par webcast et resteront disponibles pendant 30 jours sur le site web de Nurix.
Nurix Therapeutics (Nasdaq: NRIX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf zielgerichtete Proteinabbaumedikamente spezialisiert hat, hat seine Teilnahme an mehreren Investorenkonferenzen im September 2025 angek眉ndigt.
Das F眉hrungsteam, einschlie脽lich CEO Arthur T. Sands, CFO Hans van Houte, CCO John Northcott und CBO Jason Kantor, wird an f眉nf bedeutenden Gesundheitskonferenzen teilnehmen: Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley und dem Stifel Virtual Immunology Forum. Alle Pr盲sentationen werden live per Webcast 眉bertragen und sind f眉r 30 Tage 眉ber die Website von Nurix abrufbar.
- None.
- None.
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, Hans van Houte, chief financial officer, John Northcott, chief commercial officer, and Jason Kantor, Ph.D., chief business officer, will participate in several investor conferences in September.
- Wells Fargo Healthcare Conference, Boston, MA
- Fireside chat: September 3, 2025, at 1:30 p.m. ET
- H.C. Wainwright Annual Global Investment Conference, New York, NY
- Corporate presentation: September 8, 2025, at 1:30 p.m. ET
- RW Baird Healthcare Conference New York, NY
- Fireside chat: September 9, 2025, at 10:50 a.m. ET
- Morgan Stanley Healthcare Conference New York, NY
- Fireside chat: September 10, 2025, at 7:00 a.m. ET
- Stifel Virtual Immunology & Inflammation Forum
- Corporate presentation: September 16, 2025, at 11:00 a.m. ET
The fireside chats and corporate presentations will be webcast live and may be accessed via a link in the section of the Nurix website. The archived webcasts will be available for 30 days after the events.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix鈥檚 wholly owned, clinical stage pipeline includes degraders of Bruton鈥檚 tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix鈥檚 partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix鈥檚 dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine鈥檚 next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Kris Fortner
Nurix Therapeutics, Inc.
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
FAQ
When is Nurix Therapeutics (NRIX) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Nurix Therapeutics' (NRIX) conference presentations in September 2025?
Which executives from Nurix Therapeutics (NRIX) will be presenting at the September 2025 conferences?
What is Nurix Therapeutics' (NRIX) main business focus?
